

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**STA Trastuzumab deruxtecan for treating HER2-positive  
unresectable or metastatic breast cancer after 1 or more  
anti-HER2 therapies [ID3909]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE equality scheme.

**Final draft guidance**

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
N/A

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
No

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups?
--

If so, what are the barriers to, or difficulties with, access for the specific group?
No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
N/A

**Approved by Associate Director (name): Henry Edwards**

**Date:** 07/11/2022